Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
US6413523B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Feb 23, 1995 |
| Grant date | Jul 2, 2002 |
| Priority date | — |
| Expiry date | Feb 23, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel immunoregulatory utilities of Escherichi coli heat-labile enterotoxin (LT) are disclosed. This enterotoxin can be used in combination with an unrelated antigen to achieve a higher immune response to said antigen when administered as part of an oral vaccine preparation. By way of example, the efficacy of oral adjuvant therapy of LT in the development of immunological protection against herpes simplex virus was examined. In addition, the ability of LT to influence the induction and maintenance of tolerance in animals primed orally with two unrelated protein antigens administered simultaneously, OVA and BSA was examined. Simultaneous administration of LT with OVA was shown to prevent the induction of tolerance to OVA and to increase the serum anti-OVA IgG response to 30-90 fold over PBS primed and OVA primed animals, respectively.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.